Q2 2025 Biostem Technologies Inc Earnings Call Transcript
Key Points
- BioStem Technologies Inc (BSEM) delivered its sixth consecutive quarter of positive adjusted EBITDA and positive free cash flow.
- The company maintained a strong cash position, ending the quarter with $30.8 million, up from $20.6 million in Q1.
- BioStem Technologies Inc (BSEM) achieved industry-leading gross margins, with a gross profit of $48.6 million or 98.6% of net revenue.
- The company completed patient enrollment in a key clinical trial for diabetic foot ulcers, keeping them on track to report results in Q4 2025.
- BioStem Technologies Inc (BSEM) plans to expand and diversify its product portfolio through internal R&D and acquisitions, strengthening its market position.
- Net revenue decreased by 34% compared to Q2 2024, primarily due to lower sales volume and increased competition.
- The company faced reimbursement uncertainty, impacting product selection and leading to a slower start to Q2.
- BioStem Technologies Inc (BSEM) experienced heightened competitive pressure from new products with higher average sales prices.
- The proposed CMS reimbursement rule changes could significantly impact the mobile wound care market.
- GAAP net loss for the quarter was $564,000, compared to net income of $6.3 million in Q2 2024.
Thank you for standing by. My name is Eric, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioStem Technologies second-quarter 2025 earnings call. (Operator Instructions) I'd now like to turn the call over to Adam Holdsworth, Director of Investor Relations. Please go ahead.
Good afternoon, everyone, and thank you for joining our conference call to discuss BioStem's second-quarter 2025 financial results and corporate highlights. Leading the call today will be Jason Matuszewski, the company's Chairman and Chief Executive Officer; Mike Fortunato, the company's Chief Accounting Officer; and Brandon Poe, BioStem's incoming Chief Financial Officer.
Before we begin, I'd like to remind everyone that our remarks may contain forward-looking statements based on management's current expectations. These involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated.
These risks
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
